Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 2198575.
- Also identified by PMC identifier 54447.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pneumocystis carinii pneumonia is a major cause of death in AIDS patients in the United States. The presently available treatments have limited use due to a high incidence of adverse reactions. Therefore, there is an urgent need for a safer method for treatment and prevention of this disease. Recent evidence has suggested that P. carinii is related to fungi and that the wall of the cyst form contains 1,3-beta-glucan as a major constituent. Based on this, several proposed 1,3-beta-glucan synthesis inhibitors were evaluated for their ability to control P. carinii pneumonia in vivo. Compounds from two classes of 1,3-beta-glucan synthesis inhibitors, the echinocandins and papulacandins, were found to be effective against P. carinii.
Medical subject headings
- Anti-Bacterial Agents
- Glucans
- Peptides
- Pneumonia, Pneumocystis
- Pyrans